Planned
There are currently no planned studies in our center.
Ongoing
BI 1403-0032 - brigimadlin safety roll-over trial
A Phase II, single arm, open-label, long-term safety rollover trial of oral brigimadlin in patients with solid tumours
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Boehringer Ingelheim
- More information : NCT06619509
- Indication : Solid Tumors
- Internal reference number : s69421
StrateGIST-3 (GSK300383)
A Phase 3 Randomized Multicenter Open-Label Study of IDRX-42 versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : GSK
- More information : NCT07218926
- Indication :
- Internal reference number : s71062